Idarubicin-induced pigmentary changes of the nails.
A case of acute myelocytic leukemia of the FAB-M2 subtype in a patient who experienced pigmentary nail changes in conjunction with idarubicin therapy is presented. Although doxorubicin and daunorubicin have been reported to cause nail pigmentation changes, this is the first case report to describe these changes with idarubicin.
Borecky
D J
DJ
Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA.
Stephenson
J J
JJ
Keeling
J H
JH
Vukelja
S J
SJ
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000473:pathology; D015255:Idarubicin / Q000009:adverse effects* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D009260:Nail Diseases / Q000139:chemically induced*
D000903:Antibiotics, Antineoplastic; D015255:Idarubicin